Liver Cancer Control Interventions for Asian Americans
亚裔美国人的肝癌控制干预措施
基本信息
- 批准号:7914087
- 负责人:
- 金额:$ 145.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-29 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Between 1992-2000 among all cancer types, liver cancer, with its 5-year survival rate of less than 10 percent, has the distinction of having the highest annual percent increase in incidence (3.9 percent), while the incidence for the majority of other cancers declined. The highest male incidence rate of liver cancer is among Vietnamese (41.8/100,000), and the highest female incidence is among Koreans (10.0/100,000); for Hmong, the male incidence rate of 25.7/100,000 and the female incidence rate of 8.8/100,000 is intermediate between these other two groups. By contrast, the comparable incidence rates for non-Hispanic White incidence are substantially less: (male, 3.7/100,000; female, 1.5/100,000). These rates indicate that hepatitis-B related liver cancer represents the most drastic cancer health disparity affecting Asian Americans. Each of these 3 Asian groups will be the focus of this P01 entitled, "Liver Cancer Control Interventions for Asian Americans." This P01 is comprised of 3 projects: #1 "Promoting Hepatitis B Screening for Vietnamese Adults"; #2 "Community-based Hep B Interventions for Hmong Adults"; and #3 "Increasing Hep B Screening Among Korean Church Attendees." Synergy among these projects is exemplified by: having all projects focused on the same dependent variable: increasing hepatitis B serological testing rates among adults, ages 18-64; using the Health Behavior Framework; having interventions that compare effects between intervention and control conditions; having research leaders who have worked over 5 years together through the NCI's Asian American Network for Cancer Awareness Research and Training; and 2 supporting cores: Biostatistics, and Methodology. Our goals are to: (1) Conduct community-based research interventions, focused on reducing hepatitis B-induced liver cancer morbidity and mortality within these 3 Asian American populations; (2) Analyze data and lessons across projects; and (3) Report progress and share findings with the NCI, ethnic leaders, populations-at-risk and professional audiences. If these goals and the specific aims of each of these three projects are achieved, we expect the relevance of this research to public health to include the first empirically derived data on the effectiveness of community based interventions to reduce hepatitis B-induced liver cancer mortality.
描述(申请人提供):1992-2000年间,在所有癌症类型中,肝癌的五年生存率低于10%,具有发病率年增长率最高的特点(3.9%),而大多数其他癌症的发病率下降。男性肝癌发病率最高的是越南人(41.8/10万),女性发病率最高的是韩国人(10.0/10万);苗族男性发病率为25.7/10万,女性发病率为8.8/10万,介于其他两组之间。相比之下,非西班牙裔白人的可比发病率要低得多:(男性,3.7/10万;女性,1.5/10万)。这些比率表明,与乙肝相关的肝癌是影响亚裔美国人的最严重的癌症健康差距。这三个亚裔群体中的每一个都将是题为“针对亚裔美国人的肝癌控制干预”的P01的重点。这个P01由3个项目组成:#1“促进越南成年人的乙肝筛查”;#2“苗族成年人基于社区的乙肝干预措施”;以及#3“在韩国教会的信徒中增加乙肝筛查”。这些项目之间的协同作用体现在:所有项目都专注于相同的因变量:提高18岁-成年人的乙肝血清学检测率;使用健康行为框架;采取干预措施,比较干预条件和控制条件之间的效果;通过国家癌症研究所的亚裔美国人癌症意识研究和培训网络,拥有共同工作5年以上的研究负责人;以及2个支持核心:生物统计学和方法论。我们的目标是:(1)开展以社区为基础的研究干预,重点是降低这3个亚裔美国人中由乙肝引起的肝癌发病率和死亡率;(2)跨项目分析数据和经验教训;(3)与NCI、种族领袖、高危人群和专业受众报告进展并分享研究结果。如果这些目标和这三个项目中每个项目的具体目标都能实现,我们预计这项研究与公共卫生的相关性将包括关于基于社区的干预措施降低由乙肝引起的肝癌死亡率的有效性的第一批经验性数据。
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.
- DOI:10.1007/s10928-012-9251-7
- 发表时间:2012-06
- 期刊:
- 影响因子:2.5
- 作者:Dette, Holger;Pepelyshev, Andrey;Wong, Weng Kee
- 通讯作者:Wong, Weng Kee
Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study.
- DOI:10.1158/1055-9965.epi-12-1399
- 发表时间:2013-05
- 期刊:
- 影响因子:0
- 作者:Chen MS Jr;Fang DM;Stewart SL;Ly MY;Lee S;Dang JH;Nguyen TT;Maxwell AE;Bowlus CL;Bastani R;Nguyen TT
- 通讯作者:Nguyen TT
Cluster randomized trials of cancer screening interventions: Are appropriate statistical methods being used?
- DOI:10.1016/j.cct.2011.03.001
- 发表时间:2011-07-01
- 期刊:
- 影响因子:2.2
- 作者:Crespi, Catherine M.;Maxwell, Annette E.;Wu, Sheng
- 通讯作者:Wu, Sheng
Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials.
- DOI:10.1016/j.cct.2012.05.004
- 发表时间:2012-09
- 期刊:
- 影响因子:2.2
- 作者:Wu S;Crespi CM;Wong WK
- 通讯作者:Wong WK
Prevalence of hepatitis B surface antigen in US-born and foreign-born Asian/Pacific Islander college students.
- DOI:10.1080/07448481.2010.486811
- 发表时间:2010
- 期刊:
- 影响因子:0
- 作者:Quang YN;Vu J;Yuk J;Li CS;Chen M;Bowlus CL
- 通讯作者:Bowlus CL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Moon Shao-Chuang Chen其他文献
Moon Shao-Chuang Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Moon Shao-Chuang Chen', 18)}}的其他基金
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
- 批准号:
10307055 - 财政年份:2020
- 资助金额:
$ 145.87万 - 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
- 批准号:
10527364 - 财政年份:2020
- 资助金额:
$ 145.87万 - 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
- 批准号:
10093129 - 财政年份:2020
- 资助金额:
$ 145.87万 - 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
- 批准号:
9885673 - 财政年份:2020
- 资助金额:
$ 145.87万 - 项目类别:
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
AANCART:国家减少亚裔美国人癌症健康差异中心
- 批准号:
8330980 - 财政年份:2010
- 资助金额:
$ 145.87万 - 项目类别:
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
AANCART:国家减少亚裔美国人癌症健康差异中心
- 批准号:
8535317 - 财政年份:2010
- 资助金额:
$ 145.87万 - 项目类别:
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
AANCART:国家减少亚裔美国人癌症健康差异中心
- 批准号:
8911948 - 财政年份:2010
- 资助金额:
$ 145.87万 - 项目类别:
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
AANCART:国家减少亚裔美国人癌症健康差异中心
- 批准号:
8732604 - 财政年份:2010
- 资助金额:
$ 145.87万 - 项目类别:
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
AANCART:国家减少亚裔美国人癌症健康差异中心
- 批准号:
8396709 - 财政年份:2010
- 资助金额:
$ 145.87万 - 项目类别:
相似国自然基金
中国北方人群肺癌患者Cancer/Testis抗原表达谱绘制表位鉴定及功能性抗原特异性CTL制备研究
- 批准号:81673007
- 批准年份:2016
- 资助金额:54.0 万元
- 项目类别:面上项目
相似海外基金
mTORC1-dependent control of mRNA translation in liver cancer
mTORC1 依赖的肝癌 mRNA 翻译控制
- 批准号:
21K07102 - 财政年份:2021
- 资助金额:
$ 145.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting liver metabolism to control metastatic pancreatic cancer in the liver
靶向肝脏代谢来控制肝脏转移性胰腺癌
- 批准号:
21K20828 - 财政年份:2021
- 资助金额:
$ 145.87万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Epigenetic control of the metabolic tumor suppressor FBP1 in liver cancer
肝癌代谢肿瘤抑制因子 FBP1 的表观遗传控制
- 批准号:
9758641 - 财政年份:2019
- 资助金额:
$ 145.87万 - 项目类别:
Control of TCR-signalling specificity to combat liver cancer in the context of immunotherapy (P19)
在免疫治疗背景下控制 TCR 信号特异性来对抗肝癌 (P19)
- 批准号:
405445616 - 财政年份:2018
- 资助金额:
$ 145.87万 - 项目类别:
Collaborative Research Centres
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
- 批准号:
10247489 - 财政年份:2018
- 资助金额:
$ 145.87万 - 项目类别:
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
- 批准号:
10473837 - 财政年份:2018
- 资助金额:
$ 145.87万 - 项目类别:
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
- 批准号:
9792372 - 财政年份:2018
- 资助金额:
$ 145.87万 - 项目类别:
Control of stellate cells-driven liver cancer by the p62/NBR1 adapters
p62/NBR1 接头控制星状细胞驱动的肝癌
- 批准号:
9891985 - 财政年份:2016
- 资助金额:
$ 145.87万 - 项目类别:
Monitoring and control of human liver cancer ablation using real-time, 3D echo decorrelation imaging
使用实时 3D 回波去相关成像监测和控制人类肝癌消融
- 批准号:
10176156 - 财政年份:2012
- 资助金额:
$ 145.87万 - 项目类别:
Monitoring and control of human liver cancer ablation using real-time, 3D echo decorrelation imaging
使用实时 3D 回波去相关成像监测和控制人类肝癌消融
- 批准号:
9531604 - 财政年份:2012
- 资助金额:
$ 145.87万 - 项目类别: